OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Gastroenterology & Hepatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Regulating protease homeostasis in irritable bowel syndrome	855
Zolbetuximab treatment in metastatic gastric cancer	582
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	575
Hybrid EASL Congress 2023	564
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	523
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	489
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	467
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	417
Mapping neuroimmune interactions in the gut	411
Digestive Disease Week 2022	385
Western lifestyle, metaflammation and the cell of origin of colon cancer	367
2023 FDA approvals in gastroenterology and hepatology	343
Advancing nutrition science for global health	276
Black–White disparities across the colorectal cancer care continuum in the USA	265
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	262
The future of treating pancreatic exocrine insufficiency	253
Nomenclature of HBV core protein-targeting antivirals	242
Large language models for clinical decision support in gastroenterology and hepatology	225
Artificial intelligence and automation in endoscopy and surgery	225
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	208
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	207
Oral microbiome therapy efficacious for recurrent C. difficile infection	204
Wound healing in the colon	198
Hepatic IRF3 in glucose intolerance	192
New understanding of hepatobiliary MRI	187

Metastatic pancreatic cancer and the liver	182
GWAS reveals variants for alcohol-related hepatocellular carcinoma	181
Lessons from incretin-based therapy in MASH and obesity	180
Food as medicine in gastrointestinal cancer therapy	172
The global burden of coeliac disease: opportunities and challenges	168
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	167
A crucial Fusobacterium nucleatum clade in colorectal cancer	165
Inflammatory bowel disease in pregnancy and breastfeeding	153
Novel insights into chronic HBV infection	150
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	142
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	141
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	141
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	139
Integrated systems approach to identify environmental factors in intestinal inflammation	137
Characterizing the genomic landscape of colorectal cancer	137
Estimating dietary intake from human stool DNA	136
HDCA ameliorates NAFLD in mice	135
The path to successful hepatitis C elimination in Spain	133
SSRIs and depression: role of gut–brain communication	128
Human intestinal B cells in inflammatory diseases	125
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	125
Probiotics for preterms: sharing complex decision-making	121
Implications of the evolving knowledge of the genetic architecture of MASLD	120
Medical therapy of paediatric inflammatory bowel disease	115
Metabolic diseases in the East Asian populations	113
Liver, ageing and disease	113
Preventing the progression of cirrhosis to decompensation and death	109
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	107
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease	106
Current and future colorectal cancer screening strategies	105
Proteases in intestinal health and disease	104
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	100
NAFLD prevalence in older patients with T2DM	97
Phase III results for first-line treatment for metastatic colorectal cancer	93
Author Correction: Hepatic immune regulation and sex disparities	90
ECCO’24	86
The future of pathology in gastroenterology and hepatology	85
Microbiota and colorectal cancer — controlling for confounders challenges associations	85
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	83
GLP1R agonists in NAFLD: a promising therapy on the horizon	83
Enteric nervous system transfers stress to the gut	83
Transforming the landscape of liver cancer detection and care	78
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	73
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	73
Hepatic inflammatory responses in liver fibrosis	69
Hepatic glucose metabolism in the steatotic liver	67
Artificial intelligence in liver cancer — new tools for research and patient management	61
SMART cancer risk prediction	61
Liver dialysis in ACLF	59
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel	58

Elucidating the transmission landscape of the human microbiome	58
AI predicts pancreatic cancer risk	56
Hepatitis E virus: from innate sensing to adaptive immune responses	55
Pushing the frontier of gut microbiome health cross-kingdom and cross-organ	55
Gut bacteria go on record	55
A neurobiotic sense curbs feeding: a new frontier in gut–brain communication	54
International collaborative research to improve gallbladder cancer prevention	53
Nutrient sensing and small intestinal enteric neurons	52
A new era in obesity management	51
Nifty new tools for microbiome treatment design	51
MASLD as a non-communicable disease	50
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	50
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	49
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	47
Tirzepatide to treat obesity: phase III results	43
Cathepsin S in liver fibrogenesis	43
Danger! P2Y14 receptor links cell death to liver fibrosis	40
A novel pathomics signature for gastric cancer	40
Bridging the gap: increasing MENA representation in MASLD clinical trials	39
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	39
Classifying compounds as prebiotics — scientific perspectives and recommendations	38
Cellular and molecular basis of proximal small intestine disorders	38
Origin of CAFs in colorectal cancer	38
Antibiotic-perturbed microbiota and the role of probiotics	37
Therapeutic landscape and future direction of metastatic colorectal cancer	36
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	35
The steatotic liver disease burden paradox: unravelling the key role of alcohol	35
Commensal fungi in intestinal health and disease	35
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	35
Author Correction: Improving IBD outcomes in the era of many treatment options	33
Long-term normothermic liver perfusion	33
Alcohol-free and low-strength drinks: friend or foe?	33
Diet-driven microbiome restoration associated with cardiometabolic benefits	32
Changes in cholera burden across Africa	32
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	32
Justice, equity, diversity and inclusion in gastroenterology and hepatology	32
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	31
Gut virome dynamics: from commensal to critical player in health and disease	30
Public health policies to prevent alcohol-related liver disease	29
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease	29
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	29
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	28
Author Correction: Current and future colorectal cancer screening strategies	27
Global epidemiology of cirrhosis — aetiology, trends and predictions	27
Hippo signalling in the liver: role in development, regeneration and disease	27
A Roadmap for the Human Gut Cell Atlas	26
Resmetirom safe for nonalcoholic fatty liver disease	26
New target and timing in PDAC immunotherapy?	26
Digestive Disease Week 2023	25
Elafibranor in primary biliary cholangitis	25
ECCO’25	25
Location, location, location — spatial insight into hepatic macrophage populations	25
Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment	24
Positive longer-term results for efruxifermin in MASH	24
Intermittent fasting for NASH and HCC in mice	24
Digestive Disease Week 2025	24
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment	24
A resource for the food microbiome and its links with the human microbiome	24
Cholangiocarcinoma 2026: status quo, unmet needs and priorities	23
Food inequity and insecurity and MASLD: burden, challenges, and interventions	23
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	23
Envisioning how to advance the MASH field	22
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	21
Deciphering potential implications of dietary microplastics for human health	21
HCV direct-acting antiviral therapy adherence in people who inject drugs	21
Nanoparticles in NAFLD therapeutics	20
Human liver tissue in a mouse host	19
Follow-up of SER-109 for recurrent C. difficile	19
IL-17A-producing CD8+ T cells in pancreatic cancer	18
Gastrointestinal health and the environment: a bidirectional relationship	18
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	18
Lactylation and HCC progression	17
Gastrointestinal post-acute COVID-19 syndrome	17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	17
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16